Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
|
31376137 |
2019 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2-targeting properties and biodistribution were evaluated in BALB/C <i>nu/nu</i> mice bearing ovarian carcinoma cell (SKOV-3) xenografts.
|
28864631 |
2018 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that Gigantoxin-4-4D5 scFv exerted a highly cytotoxic effect on the HER2/neu-positive ovarian carcinoma SK-OV-3 cell line.
|
27063011 |
2016 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
|
26436696 |
2015 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we explored whether T-DM1 could effectively treat HER2-positive human ovarian carcinoma in vitro and in vivo.
|
24987913 |
2014 |
Ovarian Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India.
|
23722284 |
2013 |
Ovarian Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
|
17212661 |
2007 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival.
|
16785787 |
2006 |
Ovarian Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
|
16607561 |
2006 |
Ovarian Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe.
|
10409445 |
1999 |
Ovarian Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To examine the hypothesis that coamplified and/or coregulated topoisomerase IIalpha contributes to the resistance of c-erbB-2-overexpressing carcinomas, we established a chemosensitivity assay using primary cells from an ovarian carcinoma that overexpressed both c-erbB-2 and topoisomerase IIalpha.
|
10397267 |
1999 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER-2/neu is a proto-oncogene associated with poor prognosis in women with breast and ovarian carcinoma.
|
10202671 |
1999 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, intraperitoneal delivery of the anti-erbB-2 sFv enhances survival and reduces tumor burden in a xenograft model of human ovarian carcinoma in SCID mice.
|
9062138 |
1997 |
Ovarian Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, neither c-erbB2 gene amplification nor c-erbB2 protein over-expression appears to be a significant prognostic marker in patients with ovarian carcinoma.
|
7615357 |
1995 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The amplification rate of C-myc, C-N-ras, C-Ki-ras and C-erbB-2 in ovarian carcinoma were 50%, 44%, 31% and 25% respectively.
|
8585978 |
1995 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
|
7906608 |
1994 |
Ovarian Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously found that the ovarian carcinoma cell line SK-OV-3 overexpresses c-erbB-2/neu mRNA.
|
8094034 |
1993 |
Ovarian Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that amplification of the c-erb B-2/neu gene may play a role in the pathogenesis of ovarian carcinoma.
|
2569708 |
1989 |
Ovarian Carcinoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Ovarian Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|